Clinical Trials Logo

Clinical Trial Summary

This current protocol will provide the key data to help determine the specificity of our to-be-developed radiotracers by implementing a multi-site diagnostic assessment core and PET imaging of A-beta amyloid (may be completed at some sites as part of another protocol) that is commonly deposited in the brains of people with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP) or Frontotemporal Dementia (FTD) as well as healthy controls. This multicenter U19 grant is centered at U Pennsylvania (U Penn) (PI: Robert Mach) in collaboration with U Pittsburgh (Pitt), Yale University, U of California at San Francisco (UCSF) and Washington University in St. Louis (WU). U Penn will act as the single IRB of Record (sIRB) for this multi-center project and subjects will be recruited from all sites.


Clinical Trial Description

This current protocol will provide the key data to help determine the specificity of our to-be-developed radiotracers by implementing a multi-site diagnostic assessment core and PET imaging of A-beta amyloid (may be completed at some sites as part of another protocol) that is commonly deposited in the brains of people with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP) or Frontotemporal Dementia (FTD) as well as healthy controls. This multicenter U19 grant is centered at U Pennsylvania (U Penn) (PI: Robert Mach) in collaboration with U Pittsburgh (Pitt), Yale University, U of California at San Francisco (UCSF) and Washington University in St. Louis (WU). U Penn will act as the single IRB of Record (sIRB) for this multi-center project and subjects will be recruited from all sites. Sites will have local Radiation Research Safety Committee or Radioactive Drug Research Committee oversight over radiation safety related issues specific to the A-beta amyloid radiotracer used at that site (Florbetaben (18F) or 11C-PiB), if the site chooses to include A-beta amyloid PET imaging. Some sites may participate in this diagnostic assessment study without the PET/CT imaging if that data is collected as part of other studies conducted at the site. The investigators will recruit up to 10 people with PD, 10 healthy controls, 10 with MSA, 10 with PSP and 14 with FTD (4 of these FTD participants are expected tau-negative FTD controls and 10 are expected tau-positive). Key components of the multi-site diagnostic core will provide the infrastructure for these human imaging studies including regulatory activities (with a sIRB, at Penn); consistency of diagnostic criteria and clinical evaluations (with clinical consensus diagnosis of all participants); common calibration of PET scanners; model consents and protocols; and collection and distribution of clinical and imaging data. At the sites participating in A-beta amyloid PET/CT as part of this protocol, imaging will be used to evaluate A-beta amyloid deposition in the brain using well established PET A-beta amyloid radiotracers. Each subject will have one positron emission tomography (PET) or PET/computed tomography (PET/CT) scan session. Subjects with a historical positive amyloid PET scan or a negative amyloid PET scan within 2 years may not be required to undergo another scan. Prior scans will be reviewed by an investigator. Participants who are undergoing A-beta amyloid scan will undergo either approximately 20-30 minutes of static scanning or a 60 minute dynamic scan of the brain depending on the radiotracer selected at the clinical site. The standard uptake time after injection and the dose will vary depending upon which amyloid radiotracer is selected at each site. Subjects will be required to have a brain MRI performed within 12 months of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study by an investigator, they will be asked to undergo a research brain MRI after they have consented for this study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06083467
Study type Interventional
Source University of Pennsylvania
Contact Erin o Schubert
Phone 2155736569
Email erin.schubert@pennmedicine.upenn.edu
Status Recruiting
Phase Early Phase 1
Start date July 20, 2023
Completion date July 31, 2028

See also
  Status Clinical Trial Phase
Completed NCT05080777 - Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems N/A
Completed NCT03538522 - A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831 Phase 2
Recruiting NCT05508789 - A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) Phase 3
Recruiting NCT05427448 - Validation of Blood Biomarkers for Alzheimer's Disease N/A
Active, not recruiting NCT05344989 - A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants Phase 1
Recruiting NCT01696591 - The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD N/A
Withdrawn NCT05321498 - Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation Phase 2
Completed NCT04445831 - A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease Phase 1/Phase 2
Completed NCT05527288 - A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population N/A
Completed NCT02860338 - COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE N/A
Completed NCT05202223 - Harmony at Home: A Pilot Telehealth Program for Rural ADRD Caregivers N/A
Recruiting NCT05318976 - A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation Phase 2
Active, not recruiting NCT05522387 - An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease Phase 2
Completed NCT02103894 - Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects Phase 1
Recruiting NCT06303921 - Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503 Early Phase 1
Completed NCT02294851 - A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects Phase 1
Recruiting NCT06032026 - Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15 Early Phase 1
Completed NCT03938870 - CNS Tau Kinetics in Healthy Aging and Alzheimer's Disease
Completed NCT02676843 - Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations Phase 2